| Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review L Degenhardt, A Peacock, S Colledge, J Leung, J Grebely, P Vickerman, ... The Lancet Global Health 5 (12), e1192-e1207, 2017 | 1362 | 2017 |
| Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review S Larney, A Peacock, J Leung, S Colledge, M Hickman, P Vickerman, ... The Lancet Global Health 5 (12), e1208-e1220, 2017 | 448 | 2017 |
| Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ... The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018 | 301 | 2018 |
| Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs J Grebely, S Larney, A Peacock, S Colledge, J Leung, M Hickman, ... Addiction 114 (1), 150-166, 2019 | 237 | 2019 |
| Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis B Hajarizadeh, EB Cunningham, H Reid, M Law, GJ Dore, J Grebely The lancet Gastroenterology & hepatology 3 (11), 754-767, 2018 | 215 | 2018 |
| Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review S Bajis, GJ Dore, B Hajarizadeh, EB Cunningham, L Maher, J Grebely International Journal of Drug Policy 47, 34-46, 2017 | 214 | 2017 |
| Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, ... The lancet Gastroenterology & hepatology 3 (2), 125-133, 2018 | 165 | 2018 |
| Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis B Hajarizadeh, EB Cunningham, H Valerio, M Martinello, M Law, ... Journal of hepatology 72 (4), 643-657, 2020 | 143 | 2020 |
| Mixed HCV infection and reinfection in people who inject drugs—impact on therapy EB Cunningham, TL Applegate, AR Lloyd, GJ Dore, J Grebely Nature reviews Gastroenterology & hepatology 12 (4), 218-230, 2015 | 111 | 2015 |
| The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis S Colledge, A Peacock, J Leung, S Larney, J Grebely, M Hickman, ... International Journal of Drug Policy 73, 172-184, 2019 | 96 | 2019 |
| Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005‐2014: the HITS‐p study EB Cunningham, B Hajarizadeh, NA Bretana, J Amin, B Betz‐Stablein, ... Journal of viral hepatitis 24 (9), 733-741, 2017 | 90 | 2017 |
| Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study EB Cunningham, J Amin, JJ Feld, J Bruneau, O Dalgard, J Powis, ... International journal of drug policy 62, 14-23, 2018 | 80 | 2018 |
| Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study JA Kwon, GJ Dore, J Grebely, B Hajarizadeh, R Guy, EB Cunningham, ... Journal of viral hepatitis 26 (1), 83-92, 2019 | 75 | 2019 |
| Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia S Bajis, L Maher, C Treloar, B Hajarizadeh, FMJ Lamoury, Y Mowat, ... International Journal of Drug Policy 61, 23-30, 2018 | 75 | 2018 |
| Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis EB Cunningham, A Wheeler, B Hajarizadeh, CE French, R Roche, ... The lancet Gastroenterology & hepatology 7 (5), 426-445, 2022 | 66 | 2022 |
| Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study B Hajarizadeh, J Grebely, M Byrne, P Marks, J Amin, H McManus, T Butler, ... The lancet Gastroenterology & hepatology 6 (7), 533-546, 2021 | 64 | 2021 |
| Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study EB Cunningham, B Hajarizadeh, J Amin, N Bretana, GJ Dore, ... International Journal of Drug Policy 54, 18-25, 2018 | 61 | 2018 |
| Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy EB Cunningham, B Hajarizadeh, J Amin, AH Litwin, E Gane, C Cooper, ... Clinical infectious diseases 71 (7), e115-e124, 2020 | 60 | 2020 |
| Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral treatment in … S Bajis, J Grebely, B Hajarizadeh, T Applegate, AD Marshall, ... Journal of viral hepatitis 27 (3), 281-293, 2020 | 49 | 2020 |
| Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review L Degenhardt, P Webb, S Colledge-Frisby, J Ireland, A Wheeler, ... The Lancet Global Health, 2023 | 47 | 2023 |
